Fourth quarter
- Sales of
SEK 904 (855) million, an increase of 6%. In local currencies the growth was 5%. -
Sales, in local currencies increased by 16% in APAC and 6% in EMEA, while sales in
Americas decreased by 5%. - Sales in local currencies increased by 1% in Consumables and 31% in Technologies, while sales in Genetic Services decreased by 2%.
- Gross margin increased to 56.9% (54.2).
-
Operating income before depreciation and amortisation (EBITDA) was
SEK 294 (273) million, giving an EBITDA margin of 32.5% (31.9). -
Operating cash flow increased to
SEK 171 million (166). -
An impairment charge of
SEK 4,300 million is reported as other operating expenses. -
Net income was
SEK -4,179 (73) million, resulting in earnings per share ofSEK -30.86 (0.55). Excluding the impairment charge, net income increased toSEK 121 million (73), giving earnings per share ofSEK 0.89 (0.55).
Full year
- Sales of
SEK 3,512 (3,234) million, an increase of 9%, or 10% excluding discontinued business. In local currencies, growth was 4% and excluding discontinued business 5%. -
Sales, in local currencies and excluding discontinued business, increased by 16% in APAC and 6% in EMEA, while sales in
Americas decreased by 3%. - Sales, in local currencies and excluding discontinued business, increased by 9% in Consumables and 11% in Technologies, while sales in Genetic Services decreased by 1%.
- Gross margin increased to 56.3% (55.0).
-
Operating income before depreciation and amortisation (EBITDA) was
SEK 1,136 (1,050) million, giving an EBITDA margin of 32.3% (32.5). -
Operating cash flow increased to
SEK 757 million (636). -
An impairment charge of
SEK 4,300 million is reported as other operating expenses. -
Net income was
SEK -3,851 (394) million, resulting in earnings per share ofSEK -28.44 (2.91). Excluding the impairment charge, net income wasSEK 449 million (394), giving earnings per share ofSEK 3.31 (2.91).
Dividend
- The Board to propose to the Annual General Meeting a dividend of
SEK 135 (115) million, corresponding toSEK 1.00 (0.85) per share. The proposed dividend is based on exclusion of the non-cash impairment charge.
This disclosure contains information that
Contact:
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
_____________________________________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________________________________
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
https://news.cision.com/vitrolife-ab--publ-/r/fourth-quarter-and-full-year-report--2023--continued-growth-with-margin-expansions,c3921322
https://mb.cision.com/Main/1031/3921322/2579193.pdf
(c) 2024 Cision. All rights reserved., source